SAN DIEGO and TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today announced that its board of directors (the "Board") has approved, subject to required regulatory and stock exchange approvals, a plan to consolidate all of its outstanding common shares (the "Common Shares") on the ba ...

Core Viewpoint - Aptose Biosciences Inc. has entered into a common share purchase agreement with an institutional investor to raise capital for its clinical-stage oncology developments, particularly focusing on its lead drug tuspetinib for treating acute myeloid leukemia (AML) [1][5]. Group 1: Financing Agreements - The Committed Equity Facility agreement allows Aptose to sell and issue up to $25 million of its common shares over 24 months, subject to certain conditions and regulatory limitations [2]. - Aptose has also established a sales agreement for "at-the-market" (ATM) distributions on Nasdaq, with an aggregate offering price of up to $1 million [3]. Group 2: Company Overview - Aptose is a clinical-stage biotechnology company focused on developing precision medicines for unmet medical needs in oncology, with an emphasis on hematology [5]. - The company's lead product, tuspetinib (TUS), is being developed as a frontline triplet therapy for newly diagnosed AML and has shown efficacy as both a monotherapy and in combination therapy for relapsed or refractory AML [5].

TUS+VEN+AZA triplet achieves Cycle 1 complete remission (CR) in TP53-mutated/CK AMLTUS+VEN+AZA triplet achieves Cycle 1 complete remissions in FLT3-wildtype AML patientsTUS+VEN+AZA triplet shows favorable safety with no alteration of VEN and AZA dosingPK levels of TUS in the triplet remain equivalent to levels as TUS or TUS+VEN therapy SAN DIEGO and TORONTO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology compa ...

Core Insights - The TUS+VEN+AZA triplet therapy has shown promising early results in achieving complete remission in newly diagnosed acute myeloid leukemia (AML) patients, particularly those with TP53 mutations [1][3] - The therapy demonstrates a favorable safety profile, with no need for dose adjustments of venetoclax (VEN) and azacitidine (AZA) [1][3] - The TUSCANY trial aims to establish this triplet as a frontline treatment for diverse AML populations, including those traditionally difficult to treat [4][5] Company Overview - Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing precision medicines for oncology, with an emphasis on hematology [7] - The company's lead product, tuspetinib (TUS), is being evaluated as a frontline triplet therapy for newly diagnosed AML patients [7] Clinical Trial Details - The TUSCANY Phase 1/2 trial is designed to test various doses of TUS in combination with standard doses of AZA and VEN for AML patients ineligible for induction chemotherapy [5][6] - Initial data from the trial indicates that four newly diagnosed AML patients have received the lowest dose of TUS (40 mg), with two achieving complete remissions by the end of Cycle 1 [5][6] - Pharmacokinetic analyses show that TUS levels remain stable and unaffected by the addition of AZA, indicating predictable dosing without the need for adjustments [5]

Core Viewpoint - Aptose Biosciences has initiated dosing for the first patients in the TUSCANY Phase 1/2 study, evaluating the triplet therapy of tuspetinib (TUS), venetoclax (VEN), and azacitidine (AZA) for newly diagnosed acute myeloid leukemia (AML) patients [1][2][3] Group 1: Study Details - The TUSCANY Phase 1/2 trial aims to establish an improved frontline therapy for newly diagnosed AML patients, focusing on safety, durability, and broad activity across diverse AML populations [2][4] - The trial will test various doses and schedules of TUS in combination with standard doses of azacitidine and venetoclax, with TUS starting at 40mg once daily in 28-day cycles [4] - Enrollment is expected to include 18-24 patients by mid to late 2025 across multiple U.S. sites [4] Group 2: Drug Efficacy and Safety - Previous APTIVATE trials indicated that TUS as a single agent and in combination with VEN showed favorable safety and broad activity in relapsed or refractory AML populations, including those with adverse mutations [2][3] - The triplet therapy is anticipated to deliver high response rates and longer survival for newly diagnosed AML patients while minimizing toxicities associated with other treatments [3] Group 3: Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [6] - The lead clinical-stage oral kinase inhibitor, tuspetinib, has shown promise as both a monotherapy and in combination therapy for AML [6]

SAN DIEGO and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced that the Nasdaq Hearings Panel (“Panel”) has granted the Company’s request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Stock Market. On or before March 31, 2025, the Compan ...

Peer-reviewed publication details unique TUS mechanism of action TUS+VEN combination synthetic lethality overcomes resistance to VEN Tuspetinib prolongs survival in multiple AML models resistant to other drugs Findings suggest TUS will demonstrate broad antileukemic activity across AML patients TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling SAN DIEGO and TORONTO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS ...

SAN DIEGO and TORONTO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the closing of its previously announced "reasonable best efforts" public offering with participation from the CEO and existing and new healthcare focused investors for the purchase and sale of 40,000,000 common shares at a price ...

SAN DIEGO and TORONTO, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the pricing of its "reasonable best efforts" public offering with participation from the CEO and existing and new healthcare focused investors for the purchase and sale of up to 40,000,000 shares of common stock and warrants to ...

TUSCANY study is open to enroll patients to receive TUS+VEN+AZA triplet at select US sitesFavorable safety and broad clinical activity make tuspetinib an ideal agent to combine with venetoclax and azacitidine to potentially address larger AML populationsStudy execution update is expected during ASH 2024 SAN DIEGO and TORONTO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differenti ...